MedTrace Logo

Cardioprotective Effect of SGLT2-I in Diabetic Patients With AMI (SGLT2-I AMI PROTECT Study)

NCT05261867 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2022-10-24

No results posted yet for this study

Summary

Despite their potential benefits on the heart with pleiotropic mechanisms, the cardioprotective effects of new glucose-lowering SGLT-2 inhibitors in patients with myocardial infarction - both in the acute and chronic phase - have never been explored.

The key point of the project will be the evaluation of the cardioprotective effect and the potential prognostic benefit of SGLT-2 inhibitors in patients with diabetes and acute myocardial infarction.

Conditions

Sponsors & Collaborators

  • Maggiore Hospital Carlo Alberto Pizzardi

    collaborator OTHER

  • VZW Cardiovascular Research Center Aalst

    collaborator OTHER

  • Cardarelli Hospital

    collaborator OTHER

  • Azienda Ospedaliera Sant'Anna e San Sebastiano

    collaborator OTHER

  • Azienda Ospedaliera "Sant'Andrea"

    collaborator OTHER

  • Alexandrovska University Hospital

    collaborator OTHER

  • Niguarda Hospital

    collaborator OTHER

  • University of Campania Luigi Vanvitelli

    collaborator OTHER

  • ASST Grande Ospedale Metropolitano Niguarda

    collaborator OTHER

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2021-11-30
Completion
2023-01-31

Countries

  • Belgium
  • Bulgaria
  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05261867 on ClinicalTrials.gov